Back

VJHemOnc is committed to improving our service to you

iwNHL 2015 | TGR-1202, novel PI3K delta inhibitor, for hematological malignancies

VJHemOnc is committed to improving our service to you

Owen O'Connor

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Owen A. O’Connor, MD, PhD, of Columbia University, New York, NY, discusses TGR-1202, a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that is in clinical development for patients with hematological malignancies. Clinical activity and safety profile of TGR-1202 appears to be distinct from other PI3K delta inhibitors.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter